Back to Trials
NCT02346435RecruitingAccepts Healthy Volunteers

The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry

Abramson Cancer Center at Penn Medicine

Start Date

1/1/2009

Completion Date

1/1/2028

Summary

Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \<=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.

Detailed Description

All patients are offered active surveillance or immediate intervention, as applicable, prior to being offered consent for the DISSRM Registry. All patients are enrolled and followed prospectively. Surveillance patients are followed per protocol with serial imaging, blood work and quality of life questionnaires. Intervention patients are followed at the discretion of the attending surgeon with serial QOL appointments/questionnaires.

Eligibility Criteria

Age Range: 18 years to 100 years

Inclusion Criteria: * Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months. * Age ≥ 18 and able to read, understand and sign informed consent. * Must be willing to adhere to the treatment algorithm and time constraints therein. Exclusion Criteria: * Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Kidney Neoplasm

Locations

Johns Hopkins Hospital

Baltimore, Maryland 21287

United States